Heron Therapeutics
HRTX
92 hedge funds and large institutions have $848M invested in Heron Therapeutics in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 46 increasing their positions, 24 reducing their positions, and 13 closing their positions.
118% more call options, than puts
Call options by funds: $13.6M | Put options by funds: $6.25M
92% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% less capital invested
Capital invested by funds: $851M → $848M (-$2.79M)
7% less funds holding
Funds holding: 99 → 92 (-7)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$19.6M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$10.1M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$9.33M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.42M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$5.03M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.62M |
| 3 |
BC
Broadfin Capital
New York
|
-$4.2M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.18M |
| 5 |
Goldman Sachs
New York
|
-$2.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
101
Prelude Capital Management
New York
| – | -$90K | -4,747 | Closed |
|
102
Parallax Volatility Advisers
San Francisco,
California
| – | -$11.7K | -599 | Closed |
|
|
IA
103
IFP Advisors
Tampa,
Florida
| – | +$234 | +12 | New |
|
|
AG
104
Advisor Group
Phoenix,
Arizona
| – | +$371 | +19 | New |
|
HRTX Hedge Fund Activity: Q2 2016 in Review
92 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2016, worth a combined $848M — down 0.33% from $851M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HRTX and 7 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 46 added.
The largest buyer was Tang Capital Management, adding an estimated $19.6M. The largest seller was Allianz Asset Management, cutting an estimated $5.03M.
- 92 institutional investors held Heron Therapeutics (HRTX) as of Q2 2016, down from 99 in Q1 2016.
- Funds reported $848M of Heron Therapeutics stock for Q2 2016, down 0.33% quarter-over-quarter.
- 7 funds opened new Heron Therapeutics positions in Q2 2016 and 13 closed out, a net change of -6 holders.
- The largest Heron Therapeutics buyer in Q2 2016 was Tang Capital Management, an estimated $19.6M added.
- The largest Heron Therapeutics seller in Q2 2016 was Allianz Asset Management, an estimated $5.03M sold.
Based on aggregated 13F filings for Q2 2016.